相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Jasmin Wellbrock et al.
CLINICAL CANCER RESEARCH (2015)
GLI2 inhibition abrogates human leukemia stem cell dormancy
Anil Sadarangani et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened
Annelies Gonnissen et al.
ONCOTARGET (2015)
PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase
Juan M. Alonso-Dominguez et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
Jeffrey E. Lancet et al.
HAEMATOLOGICA (2015)
EBV-positive peripheral T-cell lymphoma with extensive hemophagocytosis
Mithun Vinod Shah et al.
BLOOD (2014)
Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer
Jillian Brechbiel et al.
CANCER TREATMENT REVIEWS (2014)
A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Jordi Rodon et al.
CLINICAL CANCER RESEARCH (2014)
Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1-Positive Leukemia
Seiichiro Katagiri et al.
CLINICAL CANCER RESEARCH (2013)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton et al.
BLOOD (2012)
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
Ashu Kumari et al.
BLOOD (2012)
Effects of the Hedgehog Inhibitor GDC-0449, Alone or in Combination with Dasatinib, on BCR-ABL-Positive Leukemia Cells
Seiichi Okabe et al.
STEM CELLS AND DEVELOPMENT (2012)
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Su Chu et al.
BLOOD (2011)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia
Leisl M. Packer et al.
CANCER CELL (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
Bing Long et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance
Julie Millour et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Bin Zhang et al.
CANCER CELL (2010)
Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
Hedgehog signaling maintains chemoresistance in myeloid leukemic cells
K. C. S. Queiroz et al.
ONCOGENE (2010)
Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926
Tara L. Lin et al.
PLOS ONE (2010)
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Shifeng Pan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Chen Zhao et al.
NATURE (2009)
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation
Christine Dierks et al.
CANCER CELL (2008)
Hedgehog Signaling in Development and Cancer
Jin Jiang et al.
DEVELOPMENTAL CELL (2008)
Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal
Leonard I. Zon
NATURE (2008)
Analyzing real-time PCR data by the comparative C-T method
Thomas D. Schmittgen et al.
NATURE PROTOCOLS (2008)
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
Mhairi Copland et al.
BLOOD (2008)
Essential role of stromally induced hedgehog signaling in B-cell malignancies
Christine Dierks et al.
NATURE MEDICINE (2007)
Induction of Mxi1-SRα by FOXO3a contributes to repression of Myc-dependent gene expression
Oona Delpuech et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Heather G. Jorgensen et al.
BLOOD (2007)
Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
Craig D. Peacock et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The Gli code: an information nexus regulating cell fate, stemness and cancer
Ariel Ruiz i Altaba et al.
TRENDS IN CELL BIOLOGY (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
Gene expression changes associated with progression and response in chronic myeloid leukemia
JP Radich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Expressing short hairpin RNAs in vivo
Ola Snove et al.
NATURE METHODS (2006)
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli
MS Holtz et al.
LEUKEMIA (2005)
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis
S Koschmieder et al.
BLOOD (2005)
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
R Bhatia et al.
BLOOD (2003)
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
MS Holtz et al.
BLOOD (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
分享论文
